In our penultimate video from this year’s LSX World Congress, web editor Nicole Raleigh spoke with Mike Cooke, CEO of AmacaThera, a leading developer of next-generation hydrogel-based drug delivery ...

Servier $210 million bet on IDEAYA's uveal melanoma therapy darovasertib seems to have paid off, as the drug has hit the mark in a phase 2/3 that could form the basis of regulatory filings later this ...

AI algorithms that can identify which patients are most likely to benefit from a drug recently backed for NHS use as a colorectal cancer (CRC) therapy have been developed by scien ...

The phase 1 BEHOLD-1 trial of B7-H4-directed mocertatug rezetecan (Mo-Rez, formerly HS-20093) showed an objective response rate (ORR) of 62% in platinum-resistant ovarian cancer (PROC) and 67% in ...

AstraZeneca's Lokelma therapy for high potassium levels in the blood (hyperkalaemia) should see much wider usage by the NHS after becoming one of the first medicines to be assessed under NICE's raised ...

From Eli Lilly revealing its fourth new manufacturing site in a $27 billion capital investment spree in the US – a $3.5 billion facility in Lehigh Valley, Pennsylvania – to the FDA starting to accept ...

Replimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, a decision that has led the company to accuse the agency of inconsistencies in its review of the drug.

The FDA has approved orforglipron, under the Foundayo trade name, in just 50 days, thanks to a fast track review under the ...

AZ has yet to file for approval of Imfinzi in the frontline setting for earlier-stage HCC, despite its well-established role ...

Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs), developed by longtime ...

The FDA has ramped up the pressure on Amgen to withdraw Tavneos for a rare vasculitis condition from the market, with a ...

His teams are trained to read where it will be three passes from now. In Formula 1, race strategy is no longer a gut call at ...